Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Iron is one of the most important elements required by the human body. It is one of the components of hemoglobin that transports oxygen throughout the body. High molecular weight iron dextran is the first iron product on the market for intravenous iron preparations. Hepcidin, ferritin, hemoglobin and transferrin are the major molecules that are critical in the regulation and function of iron. Due to advances in the technology of intravenous iron drugs, the development of intravenous iron drugs helps restore iron reserves in patients with iron deficiency anemia.
This report elaborates the market size, market characteristics, and market growth of the Intravenous (IV) Iron Drugs industry, and breaks down according to the type, application, and consumption area of Intravenous (IV) Iron Drugs. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Intravenous (IV) Iron Drugs in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Intravenous (IV) Iron Drugs market covered in Chapter 13:
American Regent. Inc
Daiichi Sankyo Company, Ltd.
Fresenius Medical Care AG & Co.
AMAG Pharmaceuticals. Inc.
Sanofi
Pharmacosmos A/S
Vifor Pharma Management Ltd.
Shield Therapeutics Plc
Rockwell Medical Technologies, Inc.
Allergan, Inc.
In Chapter 6, on the basis of types, the Intravenous (IV) Iron Drugs market from 2015 to 2025 is primarily split into:
Iron Isomaltoside
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
In Chapter 7, on the basis of applications, the Intravenous (IV) Iron Drugs market from 2015 to 2025 covers:
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Other Diseases
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others
2019
This report elaborates the market size, market characteristics, and market growth of the Intravenous (IV) Iron Drugs industry, and breaks down according to the type, application, and consumption area of Intravenous (IV) Iron Drugs. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Intravenous (IV) Iron Drugs in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Intravenous (IV) Iron Drugs market covered in Chapter 13:
American Regent. Inc
Daiichi Sankyo Company, Ltd.
Fresenius Medical Care AG & Co.
AMAG Pharmaceuticals. Inc.
Sanofi
Pharmacosmos A/S
Vifor Pharma Management Ltd.
Shield Therapeutics Plc
Rockwell Medical Technologies, Inc.
Allergan, Inc.
In Chapter 6, on the basis of types, the Intravenous (IV) Iron Drugs market from 2015 to 2025 is primarily split into:
Iron Isomaltoside
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
In Chapter 7, on the basis of applications, the Intravenous (IV) Iron Drugs market from 2015 to 2025 covers:
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Other Diseases
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others
Years considered for this report:
Historical Years:
2015-2019Base Year:
2019Estimated Year:
2020Forecast Period:
2020-2025Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
